Herbert L. Kotz

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

Nilofer S. Azad, Edwin M. Posadas, Virginia E. Kwitkowski et al. · Journal of Clinical Oncology · 2008 · 337 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

James L. Gulley, Philip M. Arlen, Kwong-Yok Tsang et al. · Clinical Cancer Research · 2008 · 229 citations · Full text

Medicine, Immunology, Oncology +17

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors

William L. Dahut, Nehal J. Lakhani, James L. Gulley et al. · Cancer Biology & Therapy · 2006 · 156 citations

Pharmacy, Oncology, Pharmacology +15

Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer

Mahrukh M. Hussain, Herbert L. Kotz, Lori M. Minasian et al. · Journal of Clinical Oncology · 2003 · 89 citations

Medicine, Oncology, Pharmacology +17

Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

Christina M. Annunziata, Amanda J. Walker, Lori M. Minasian et al. · Clinical Cancer Research · 2010 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17